Related Experiment Video

Updated: May 3, 2026

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy
10:10

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

5.7K

The validity of serum markers for fibrosis staging in chronic hepatitis B and C

J Li1, S C Gordon, L B Rupp

  • 1Henry Ford Health System, Detroit, MI, USA.

Journal of Viral Hepatitis
|January 30, 2014
PubMed

Insights

The FIB-4 score accurately assesses liver fibrosis in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) patients. This non-invasive method aids in managing liver disease by predicting advanced fibrosis and cirrhosis.

Area of Science:

  • Hepatology
  • Biomarker Development
  • Diagnostic Accuracy

Background:

  • Accurate assessment of liver fibrosis is crucial for managing chronic hepatitis B (CHB) and chronic hepatitis C (CHC).
  • Non-invasive serum markers offer a reproducible and accessible alternative to liver biopsy for fibrosis staging.
  • Existing serum marker indices require validation and optimization for clinical application.

Purpose of the Study:

  • To expand and validate serum marker indices for accurate, reproducible, and easily applied liver fibrosis assessment.
  • To derive and validate optimal cut-offs for differentiating fibrosis levels using a novel algorithm.
  • To compare the predictive performance of FIB-4 and APRI scores in CHB and CHC patients.

Main Methods:

  • Liver biopsy results from 284 CHB and 2304 CHC patients were mapped to an F0-F4 fibrosis scale.
  • APRI and FIB-4 scores were calculated within a 6-month window of biopsy and mapped to the same scale.
  • A novel algorithm was used to derive and validate optimal cut-offs for fibrosis level differentiation.

Main Results:

  • The FIB-4 score demonstrated superior prediction of advanced fibrosis and cirrhosis in CHC patients compared to other serum markers.
  • FIB-4 showed similar performance to APRI in CHB patients for predicting advanced fibrosis and cirrhosis.
  • The area under the receiver operating characteristic curves (AUROC) for FIB-4 was 0.86 for CHB and 0.83 for CHC in differentiating F3-F4 from F0-F2.
  • Validated FIB-4 cut-offs yielded high positive predictive values for identifying non-fibrotic (F0-F2) and cirrhotic (F4) stages.

Conclusions:

  • The FIB-4 score accurately predicts the upper and lower ends of liver fibrosis stages (cirrhosis and F0-F2) in both CHB and CHC patients.
  • FIB-4 serves as a reliable non-invasive tool for assessing liver fibrosis, supporting individualized disease management.
  • Optimized FIB-4 cut-offs enhance its utility in clinical practice for diagnosing liver fibrosis stages.

Keywords:
APRIFIB-4chronic hepatitiscomparative effectivenessliver stage predictionserum markers of fibrosis

More Related Videos

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

2.2K
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

56.5K

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86